Valuation: Forte Biosciences, Inc.

Market Cap 1.07B 941M 872M 802M 1.52B 103B 1.55B 10.39B 4.08B 50.44B 4.03B 3.94B 174B P/E 2026 *
-10.7x
P/E 2027 * -10.3x
Enterprise Value 1.07B 941M 872M 802M 1.52B 103B 1.55B 10.39B 4.08B 50.44B 4.03B 3.94B 174B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
97.86%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Forte Biosciences, Inc.

1 day-5.48%
1 week+97.94%
Current month+90.12%
1 month+123.82%
3 months+32.03%
6 months+24.35%
Current year+48.15%
1 week 20.2
Extreme 20.2
45.36
1 month 16.89
Extreme 16.89
45.36
Current year 15.51
Extreme 15.51
45.36
1 year 9.1
Extreme 9.1
45.36
3 years 4.11
Extreme 4.11
45.36
5 years 4.11
Extreme 4.11
921.25
10 years 4.11
Extreme 4.11
1,349.75
Manager TitleAgeSince
Chief Executive Officer 55 01/01/2018
Director of Finance/CFO 59 01/03/2020
Chief Operating Officer - 01/10/2020
Director TitleAgeSince
Chairman 55 -
Director/Board Member 58 01/06/2020
Director/Board Member 79 16/03/2022
Date Insider Type Main position Quantity % Market Cap.
07-01Fiscal year

Chief Financial Officer

884 0.0043%
07-01Fiscal year

Chief Executive Officer

2,598 0.0127%
06-16Free

Chief Financial Officer

22,000 0.1074%
Change 5-day change 1-year change 3-year change Capi.($)
-5.48%+97.94%+310.78%+60.00% 1.07B
-2.48%-3.13%+55.85%+89.65% 54.88B
-0.55%-6.57%+55.85%+128.31% 54.63B
-5.32%-2.02%+7.26%+421.17% 25.06B
-0.55%-3.23%-18.11%-16.99% 23.14B
-1.69%-0.64%+40.04%-0.48% 19.87B
+1.87%+4.16%+38.74%-26.42% 17.55B
-2.72%-0.60%+187.08%+351.91% 16.5B
-2.42%+1.00%+48.24%+635.77% 15.75B
-1.49%+0.27%+22.16%+187.75% 14.2B
Average -2.09%+10.26%+74.79%+183.07% 24.26B
Weighted average by Cap. -1.74%-1.07%+48.84%+165.54%

Financials

2026 *2027 *
Net sales - -
Net income -95.54M -83.8M -77.61M -71.41M -135M -9.14B -138M -925M -363M -4.49B -359M -351M -15.51B -130M -114M -106M -97.49M -184M -12.48B -188M -1.26B -495M -6.13B -490M -479M -21.17B
Net Debt - -
Logo Forte Biosciences, Inc.
Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company that is advancing FB102, which is an anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. It is advancing clinical development of FB102 into patient-based trials for celiac disease and non-segmental vitiligo. The Company's FB102 program focuses on addressing key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and certain T cell subsets. FB102 has potentially other autoimmune and autoimmune-related applications including vitiligo, alopecia areata, and type 1 diabetes (T1D). Its subsidiaries include Forte Subsidiary, Inc. and Forte Biosciences Australia Proprietary Limited.
Employees
22
Date Price Change Volume
14/07/26 US$40.62 -7.53% 287,575
10/07/26 US$43.92 +19.67% 3,191,577
09/07/26 US$36.70 +78.33% 4,866,491
08/07/26 US$20.58 -7.51% 590,078
07/07/26 US$22.25 +9.02% 500,708
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
43.92USD
Average target price
64.75USD
Spread / Average Target
+47.43%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. FBRX Stock